SSY Group (02005.HK): Obtains Production Registration Approvals for Three Products; Fat-Soluble Vitamin Injection Approved as First Domestic Enterprise

NewTimeSpace News: SSY Group Limited (02005.HK) released a voluntary announcement on May 6, 2026, disclosing the latest progress in product development.

For Fat-Soluble Vitamin Injection (Ⅰ) (10ml), the Group is the first domestic enterprise to obtain the drug production registration approval from the NMPA. Classified as a Class 3 chemical drug, it is deemed to have passed the consistency evaluation. This product is mainly used for children and infants under 11 years old as a supplement to intravenous nutrition to meet daily requirements of fat-soluble vitamins A, D2, E and K1.

For Metformin Hydrochloride Tablets (0.5g and 0.25g), the Group has obtained the drug production registration approval from the NMPA. Classified as a Class 4 chemical drug, it is deemed to have passed the consistency evaluation. This product is mainly used for the treatment of type 2 diabetes mellitus when blood glucose cannot be controlled by diet and exercise alone.

For Doxazosin Mesylate Extended-Release Tablets (4mg), the Group has obtained the drug production registration approval from the NMPA. Classified as a Class 4 chemical drug, it is deemed to have passed the consistency evaluation. This product is mainly used for the symptomatic treatment of benign prostatic hyperplasia and the treatment of hypertension. Previously, the Group’s doxazosin mesylate active pharmaceutical ingredient (API) has been approved by the NMPA for use in marketed preparations.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.